FDA Approves Saxenda for Weight Management

Share this content:
FDA Approves Saxenda for Weight Management
FDA Approves Saxenda for Weight Management

(HealthDay News) -- Saxenda (liraglutide [rDNA origin] injection) has been approved by the U.S. Food and Drug Administration as a treatment option for chronic weight management, along with a reduced-calorie diet and physical activity.

The injected drug is approved for people with a body mass index (BMI) of 30 kg/m² or greater, or for those with a BMI of 27 kg/m² or greater who have at least one other weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia.

Saxenda, a glucagon-like peptide-1 receptor agonist, shouldn't be used in combination with other medications in that class. This includes the diabetes treatment Victoza, which has the same active ingredient (liraglutide) at a different dose (1.8 mg, versus 3 mg for Saxenda). Saxenda has not been evaluated to treat diabetes and should not be used for this purpose.

The medication's safety and effectiveness were evaluated in three clinical studies involving 4,800 people. In one study, some 62 percent of people who took Saxenda lost at least 5 percent of their body weight, compared with 34 percent of those who took a placebo. Saxenda's label includes a warning that thyroid tumors were observed in rats given Saxenda, although the same effect hasn't been established among people, the FDA said. Serious adverse reactions included pancreatitis, gallbladder disease, renal impairment, and suicidal thoughts. More common side effects were nausea, diarrhea, constipation, vomiting, hypoglycemia, and loss of appetite.

The drug is produced by Novo Nordisk, based in Bagsvaerd, Denmark.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »